Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.43 |
| ▸ | KDM5A | P29375 | 3/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.43 |
| ▸ | KDM4A | O75164 | 2/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL3877293 | 0.90 | HDAC6 (0.36) | KDM4CKDM5AKDM5BKDM4AAKR1B1 | |
| SCHEMBL3881934 | 0.81 | KDM5A (0.55) | KDM4CKDM5AKDM5BKDM4AVNN1 | |
| SCHEMBL3873546 | 0.78 | KDM5B (0.51) | KDM4CKDM5AKDM5BKDM4AHDAC6 | |
| SCHEMBL3877779 | 0.76 | ALDH1A1 (0.48) | KDM4CKDM5AKDM5BKDM4AMEN1 | |
| SCHEMBL3873000 | 0.76 | KDM4C (0.51) | KDM4CKDM5AKDM5BKDM4AMAPT | |
| SCHEMBL3886892 | 0.74 | KDM4C (0.57) | KDM4CKDM5AKDM5BVNN1HDAC6 | |
| SCHEMBL3881010 | 0.74 | CDK5 (0.51) | VNN1PTGER4ALDH1A1 | |
| SCHEMBL3874614 | 0.73 | KDM4C (0.49) | KDM4CKDM5AKDM5BKDM4A | |
| SCHEMBL3873027 | 0.73 | KDM5B (0.47) | KDM4CKDM5AKDM5BKDM4AMEN1 | |
| SCHEMBL3878702 | 0.72 | SMN1; SMN2 (0.54) | HDAC1PTGER4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673955-B2 | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them | MERCK PATENT GMBH (DE) | 2014-03-18 | — | — | US | claimed |
| EP-1910305-B1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2009-08-26 | — | — | EP | claimed |
| US-20080312299-A1 | Imidazole Derivatives as Fructose-1,6-Bisphosphatase Inhibitors and Pharmaceutical Compositions Containing Them | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-18 | — | — | US | claimed |
| EP-1910305-A1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Merck Patent GmbH (DE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007019937-A1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2007-02-22 | — | — | WO | claimed |
| EP-1752450-A1 | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them | Merck Sante (FR) | 2007-02-14 | — | — | EP | claimed |
| US-8673955-B2 | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them | MERCK PATENT GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| EP-1910305-B1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-20080312299-A1 | Imidazole Derivatives as Fructose-1,6-Bisphosphatase Inhibitors and Pharmaceutical Compositions Containing Them | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-18 | — | — | US | disclosed |
| EP-1910305-A1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Merck Patent GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007019937-A1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
| EP-1752450-A1 | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them | Merck Sante (FR) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312299-A1 | Imidazole Derivatives as Fructose-1,6-Bisphosphatase Inhibitors and Pharmaceutical Compositions Containing Them | FBP1, ALDOA, GYS2 | KDM4C 3197/4885KDM5A 2180/4885KDM5B 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.